Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
Whether you are a medical oncologist, a surgical oncologist, a radiotherapist, or a pathologist, this is your opportunity to explore new therapeutic discoveries and research perspectives.
Register for this live discussion based on the widely used ESMO Guidelines and help patients with the best care option
A new series for a deeper understanding of upper GI cancers. Join the exchange with top experts and advance your knowledge in these tumour types.
The latest insights in the diagnosis, biology and therapy of gynaecological cancers
A live discussion of the most updated data on efficacy and safety, research progress and therapeutic interventions beyond SARS-CoV-2 vaccines
Do not miss the opportunity! Submit your application by 24 January 2022
Discover the new digital only edition and get the most out of Annals Of Oncology online version
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
An in-depth reflection on gaps in medical knowledge and research with Emmanouil Saloustros and Liz Margolies
ESMO is pleased to announce that the Patient Guide in Non-Small-Cell Lung Cancer is now available in 9 different languages
Genetic subtyping more accurately reflects clinical behaviour than reliance on pathologic classification only
Findings from the COMBI-I study
Final overall survival analysis from the HER2CLIMB study
The ESMO Sarcoma & GIST Symposium 2022, will be held as a virtual event.
Findings from the FinXX study
Findings from the International Replication Repair Deficiency Consortium registry-based study
Findings from the GOG-0261 study
ESMO is now pleased to announce that the Patient Guide in Breast Cancer is now available in 14 different languages
Tislelizumab in combination with gemcitabine and cisplatin prolonged PFS compared with chemotherapy alone in the RATIONALE 309 study
Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups
A study associates reductions in ctDNA with major pathologic response following neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC, but clinical application is still some way off
Results from an exploratory analysis of the IMpower010 trial confirm that there is a correlation between tumour-cell PD-L1 expression and disease-free survival
Early clinical findings with the anti-claudin-6 CAR-T-cell product BNT211, with or without amplifying vaccine, in patients with refractory solid tumours are promising but more data are required
Data suggest that assessing the quality as well as the quantity of tumour mutations may enhance prediction of outcomes in patients treated with immune checkpoint inhibitors
From cell-based therapies to soluble T-cell engagers and T-cell co-stimulation, early findings show novel promising strategies, although more data are needed
Along with treatments with immune checkpoint inhibitors and cellular therapies, other immunotherapies are currently under investigation
Immunotherapy plus chemotherapy as first-line treatment choice for advanced disease without oncogene mutations, irrespective of ethnicity and PD-L1 status
Genetic subtyping more accurately reflects clinical behaviour than reliance on pathologic classification only
Findings from the COMBI-I study
Final overall survival analysis from the HER2CLIMB study
Findings from the FinXX study
Findings from the International Replication Repair Deficiency Consortium registry-based study
Findings from the GOG-0261 study
Efficacy and safety data in a larger number of patients and longer follow-up from KEYNOTE-158 study
Patients with cancer who develop breakthrough COVID-19 remain at risk of severe outcomes despite full vaccination
Findings from a meta-analysis of two randomised controlled phase III studies of the STAMPEDE platform protocol
The ESMO Sarcoma & GIST Symposium 2022, will be held as a virtual event.
The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.
Results of the ESMO Women for Oncology monitoring and authorship studies
The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
First concrete results presented at the ESMO Congress 2021 confirm need to promote vaccination in patients with cancer
FIRSTMAPPP, the first randomised study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months
The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial
Based on current knowledge available, they address key questions on safety and efficacy of COVID-19 vaccines, their interference with anticancer treatment, and advocate for a global strategy for the booster dose
ESMO President will act as an Advisor
Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on
ESMO delivered an official statement at the Special Session of the World Health Assembly to strengthen pandemic prevention, preparedness and response
The ESMO Immuno-Oncology Congress will be an online-only meeting
The collaborative study shows significant gaps in low- and middle-income countries
ESMO has announced today that the 2021 ESMO Award for Immuno-oncology is presented to Hervé Fridman
ESMO has announced today the winners of the 2021 Society Awards.
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Resources such as abstracts, presentations and webcasts from meetings can be accessed by ESMO members and conference delegates throughout all the year
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
South Africa
Belgium
Mexico
Mexico
Czech Republic
Germany
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the CME test with E-learning and V-learning modules
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
